1型糖尿病に対する幹細胞療法の進展（Progress in stem cell therapy for type 1 diabetes）

2026-04-17 カロリンスカ研究所（KI）

＜関連情報＞

• https://news.ki.se/progress-in-stem-cell-therapy-for-type-1-diabetes
• https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(26)00103-7

複数のヒト多能性幹細胞株から膵島を効率的に誘導するための最適化されたプロトコル An optimized protocol for efficient derivation of pancreatic islets from multiple human pluripotent stem cell lines

Siqin Wu ∙ Shivam Chandel ∙ Galyna Bryzgalova ∙ … ∙ My Hedhammar ∙ Per-Olof Berggren ∙ Fredrik Lanner
Stem Cell Reports  Published:April 16, 2026
DOI:https://doi.org/10.1016/j.stemcr.2026.102892

Graphical abstract

Highlights

• Differentiation to pancreatic endocrine progenitors is highly efficient on laminin-521
• Transfer from 2D to 3D culture yields functional SC-islets free of non-endocrine cells
• Glucose responsive SC-islets are generated from all tested hPSC lines
• The anterior chamber of the eye enables SC-islet transplantation and functional analysis

Summary

The success of cell therapy for type 1 diabetes (T1D) depends on reliable differentiation of stem cells into functional pancreatic islets. Current protocols produce stem cell-derived islets (SC-islets) that contain non-endocrine cells and show limited maturity. We developed a robust protocol that generates functional SC-islets from all eight tested human pluripotent stem cell (hPSC) lines. Differentiation to the endocrine progenitor (EP) stage on 2D laminin-521 is improved by shortening the prior pancreatic progenitor (PP) stage. Notably, allowing EP cells to self-aggregate efficiently removes proliferative and non-endocrine cells. Subsequent suspension culture yields SC-islets with strong glucose responsiveness in vitro. After transplantation into the anterior chamber of the eye of diabetic mice, SC-islets further mature and restore normal glycemic control. Single-cell analyses show that the SC-islets are free of non-endocrine cell populations before and after transplantation. This protocol enables production of highly functional SC-islets suitable for T1D cell therapy.